Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
1. |
ECCT/25/03/01 | MK-5684_MSD (mCRPC) A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) |
Principal Investigator(s) 1. PROF MANSOOR NOORALI SALEH Site(s) in Kenya AGA KHAN UNIVERSITY HOSPITAL NAIROBI |
View |
2. |
ECCT/25/02/09 | DASH II Study Diagnostic Access to Self-Care & Health Services in Low- and Middle-Income Countries (DASH) – Phase II Study |
Principal Investigator(s) 1. ELIZABETH ANNE BUKUSI Site(s) in Kenya Migori County |
View |
3. |
ECCT/25/02/08 | Clearance of High-Risk HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Valentine Chepkorir Sing’oei Site(s) in Kenya 1. KEMRI –USAMRD-A, Kombewa Clinical Research Centre (Kisumu county) |
View |
4. |
ECCT/25/02/07 | Clearance of High-Risk HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya 1. KEMRI-RCTP (Kisumu county) |
View |
5. |
ECCT/25/02/06 | Clearance of High-Risk HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya 1. KAVI-Institute of Clinical Research (KAVI - ICR) (Nairobi City county) |
View |